Answers are grounded in this paper and cite their sources.
Differential splicing has been extensively characterized at the level of individual splicing events, yet a systematic pan-cancer characterization of transcript-driven subcellular localization switching is lacking. Using matched tumour and healthy tissue samples across 14 TCGA cancer types, we predicted the subcellular localization of every protein-coding isoform and grouped transcript expression into three localization classes: transmembrane/cell surface (TM), secreted (Sec), and intracellular (Int). We defined a localization switch as a tumour-associated redistribution of transcript usage between these localization classes and identified 977 genes, corresponding to 3,723 gene-by-cancer localization-switch events, many of which recurred across multiple cancer types. Among these, we highlight representative switches with potential implications for immune regulation, intrinsic cancer-cell function, and soluble decoy formation. Together, our results establish transcript-driven subcellular localization switching as a recurrent consequence of alternative splicing in cancer and provide a framework and resource for investigating its potential roles in immune evasion, therapeutic resistance, and cancer adaptation.
No takes yet. Share an insight, caveat, or question.
Cerro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: